ABT

130.98

0.99% 1.28

Handel nachbörslich: 131.83 0.85 +0.65%

Abbott Laboratories (ABT)

Überblick Nachrichten Preisverlauf Optionskette Financials Forum Prognose Aktiensplit Dividendenhistorie

Schlusskurs vom Vortag:

$129.70

Offen:

$130.375

24-Stunden-Volumen:

10.46M

Relative Volume:

1.47

Marktkapitalisierung:

$221.92B

Einnahmen:

$41.95B

Nettoeinkommen (Verlust:

$13.40B

KGV:

17.12

EPS:

7.65

Netto-Cashflow:

$6.35B

1W Leistung:

+5.20%

1M Leistung:

+2.62%

6M Leistung:

+11.10%

1J Leistung:

+23.68%

1-Tages-Spanne:

$129.66

$132.71

1-Wochen-Bereich:

$124.04

$134.16

52-Wochen-Spanne:

$99.71

$140.84

Abbott Laboratories Stock (ABT) Company Profile

Firmenname

Abbott Laboratories

Sektor

Healthcare (1151)

Branche

Medical Devices (153)

Telefon

(224) 667-6100

Adresse

100 ABBOTT PARK ROAD, ABBOTT PARK, IL

Mitarbeiter

114,000

Twitter

@AbbottNews

Nächster Verdiensttermin

2025-04-16

Neueste SEC-Einreichungen

ABT's Discussions on Twitter

Vergleichen Sie ABT mit anderen Aktien

Aktien	Preis	Marktkapitalisierung	Umsatz	Nettogewinn	Free Cashflow	ENV
ABT Abbott Laboratories	130.98	221.92B	41.95B	13.40B	6.35B	7.65
BSX Boston Scientific Corp	95.12	139.43B	16.75B	1.85B	2.37B	1.25
SYK Stryker Corp	346.50	134.90B	22.60B	2.99B	3.49B	7.76
MDT Medtronic Plc	82.60	108.02B	33.20B	4.26B	5.47B	3.29
EW Edwards Lifesciences Corp	71.53	40.93B	5.72B	4.17B	259.90M	6.97

Abbott Laboratories Stock (ABT) Upgrades & Downgrades

Datum	Aktion	Analytiker	Ratingänderung
2024-10-08	Eingeleitet	Oppenheimer	Outperform
2024-09-19	Eingeleitet	Piper Sandler	Overweight
2024-07-30	Herabstufung	Edward Jones	Buy → Hold
2024-05-30	Eingeleitet	Goldman	Buy
2023-07-21	Hochstufung	Wolfe Research	Underperform → Peer Perform
2023-05-30	Herabstufung	Morgan Stanley	Overweight → Equal-Weight
2023-04-20	Bestätigt	Barclays	Overweight
2023-04-20	Bestätigt	Bernstein	Outperform
2023-04-20	Bestätigt	JP Morgan	Overweight
2023-04-20	Bestätigt	Raymond James	Outperform
2023-04-20	Bestätigt	UBS	Buy
2023-04-20	Bestätigt	Wolfe Research	Underperform
2023-03-29	Eingeleitet	UBS	Buy
2022-10-26	Eingeleitet	Mizuho	Neutral
2022-10-18	Eingeleitet	Barclays	Overweight
2022-10-12	Eingeleitet	Jefferies	Hold
2022-07-06	Eingeleitet	Wolfe Research	Underperform
2022-03-02	Fortgesetzt	BofA Securities	Buy
2022-01-27	Bestätigt	Credit Suisse	Outperform
2022-01-27	Bestätigt	Morgan Stanley	Overweight
2022-01-27	Bestätigt	Raymond James	Outperform
2022-01-27	Bestätigt	UBS	Buy
2021-12-10	Eingeleitet	RBC Capital Mkts	Outperform
2021-10-27	Hochstufung	Atlantic Equities	Neutral → Overweight
2021-10-14	Eingeleitet	Redburn	Neutral
2021-05-25	Eingeleitet	Barclays	Overweight
2021-04-15	Eingeleitet	Atlantic Equities	Neutral
2021-01-28	Hochstufung	BTIG Research	Neutral → Buy
2020-09-11	Eingeleitet	Wolfe Research	Outperform
2020-06-01	Herabstufung	Goldman	Neutral → Sell
2020-03-05	Eingeleitet	Citigroup	Buy
2020-02-13	Eingeleitet	Goldman	Neutral
2020-02-06	Fortgesetzt	BTIG Research	Neutral
2020-01-02	Herabstufung	Guggenheim	Buy → Neutral
2019-06-13	Bestätigt	BofA/Merrill	Buy
2019-02-07	Bestätigt	BofA/Merrill	Buy
2019-01-02	Herabstufung	Citigroup	Neutral → Sell
2018-11-30	Hochstufung	Goldman	Neutral → Buy
2018-10-16	Eingeleitet	Barclays	Overweight
2018-06-27	Eingeleitet	Bernstein	Outperform
2018-01-30	Bestätigt	Citigroup	Neutral
2018-01-25	Bestätigt	Stifel	Buy
2018-01-25	Hochstufung	William Blair	Mkt Perform → Outperform
2018-01-03	Eingeleitet	Evercore ISI	Outperform
2018-01-02	Hochstufung	JP Morgan	Neutral → Overweight
2018-01-02	Hochstufung	Morgan Stanley	Equal-Weight → Overweight
2017-10-19	Bestätigt	RBC Capital Mkts	Outperform
2017-10-19	Bestätigt	Stifel	Buy

Alle ansehen

Abbott Laboratories Aktie (ABT) Neueste Nachrichten

12:09 PM

Abbott expects a ‘few hundred million’ in tariff costs in 2025 - Manufacturing Dive

12:09 PM

09:10 AM

Abbott Laboratories Plans $500M Manufacturing, R&D Expansion In DFW and Chicago - Bisnow

Apr 17, 2025

Abbott Laboratories Adjusts Financial Outlook With Increased Price Target - Evrim Ağacı

Apr 17, 2025

Abbott Laboratories First Quarter 2025 Earnings: EPS Misses Expectations - simplywall.st

Apr 17, 2025

RBC Capital lifts Abbott Labs target to $145, maintains Outperform By Investing.com - Investing.com India

Apr 17, 2025

Abbott Labs stock target raised to $144 by Bernstein SocGen - Investing.com India

Apr 17, 2025

RBC Capital lifts Abbott Labs target to $145, maintains Outperform - Investing.com

Apr 17, 2025

UBS maintains Buy on Abbott Labs with $148 price target By Investing.com - Investing.com India

Apr 17, 2025

Abbott price target raised to $140 from $138 at Evercore ISI - Yahoo Finance

Apr 17, 2025

Abbott Labs (ABT) Stock: Earnings Beat with Strong MedTech Growth and $500M U.S. Investment - CoinCentral

Apr 17, 2025

UBS maintains Buy on Abbott Labs with $148 price target - Investing.com

Apr 17, 2025

These Analysts Boost Their Forecasts On Abbott Laboratories After Better-Than-Expected Earnings - Benzinga

Apr 17, 2025

Piper Sandler raises Abbott Labs target to $145, keeps Overweight By Investing.com - Investing.com India

Apr 17, 2025

Piper Sandler raises Abbott Labs target to $145, keeps Overweight - Investing.com

Apr 17, 2025

Citi Reaffirms Their Buy Rating on Abbott Laboratories (ABT) - The Globe and Mail

Apr 17, 2025

Demystifying Abbott Laboratories: Insights From 11 Analyst Reviews - Benzinga

Apr 17, 2025

RBC Capital Increases Price Target for Abbott (ABT) to $145 | ABT Stock News - GuruFocus

Apr 17, 2025

Stifel cuts Abbott Labs stock target to $135, maintains buy rating - Investing.com India

Apr 17, 2025

Abbott Laboratories: Strong Performance and Strategic Positioning Drive Buy Rating - TipRanks

Apr 17, 2025

Oppenheimer Increases Price Target for Abbott (ABT) to $140 | ABT Stock News - GuruFocus

Apr 17, 2025